Opexa Therapeutics' ongoing development program for Tovaxin to be presented

Sep 8 2009

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin^®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 11^th Annual Healthcare Conference. The conference will be held September 9-11, 2009, at the Palace Hotel in New York City.

Opexa’s presentation will take place at 10:50 a.m. (EST) on Friday, September 11, 2009 in the Henry Salon (5^th floor) of the NY Palace Hotel. The presentation will include an overview of the company’s ongoing development program for Tovaxin, the company’s lead therapy for MS and an overview of the recently announced stem cell agreement with Novartis. The presentation will be webcasted and the link to access the audio webcast and presentation will be available at www.opexatherapeutics.com.